Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Mosca

Showing results (351-360 of 377) with videos related to

Pageof 38
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2020
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life SettingMariele Gatto, Francesca Saccon, Margherita Zen, et al.
Journal of Personalized Medicine|April 28, 2023
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS)Margherita Zen, Mariele Gatto, Roberto Depascale, et al.
Clinical and Experimental Rheumatology|March 14, 2023
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody productsRosaria Talarico, Giuseppe Alvise Ramirez, Sofia C Barreira, et al.
Lupus Science & Medicine|May 6, 2025
Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi studyKathryn Connelly, Rachel Koelmeyer, Darshini Ayton, et al.
Frontiers in Public Health|June 26, 2026
European Reference Networks as core health structures where referring genetic newborn screening positive infants: an innovative operational research frameworkFernanda Fortunato, Rita Selvatici, Jan Kirschner, et al.
Annals of the Rheumatic Diseases|November 26, 2016
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)Ronald van Vollenhoven, Alexandre Voskuyl, George Bertsias, et al.
Arthritis Care & Research|December 28, 2021
Evaluating the Construct of Damage in Systemic Lupus ErythematosusSindhu R Johnson, Dafna D Gladman, Hermine I Brunner, et al.
Nature Reviews. Rheumatology|October 6, 2022
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNETRosaria Talarico, Silvia Aguilera, Tobias Alexander, et al.
Arthritis and Rheumatism|January 4, 2012
Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter studyMara Taraborelli, Véronique Ramoni, Antonio Brucato, et al.
Clinical Reviews in Allergy & Immunology|March 16, 2021
Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected IndividualsLaura Andreoli, Cecilia Nalli, Maria Grazia Lazzaroni, et al.
Pageof 38

Showing results (351-360 of 377) with videos related to

Sort By:
Pageof 38
Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2020
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life SettingMariele Gatto, Francesca Saccon, Margherita Zen, et al.
Journal of Personalized Medicine|April 28, 2023
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS)Margherita Zen, Mariele Gatto, Roberto Depascale, et al.
Clinical and Experimental Rheumatology|March 14, 2023
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody productsRosaria Talarico, Giuseppe Alvise Ramirez, Sofia C Barreira, et al.
Lupus Science & Medicine|May 6, 2025
Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi studyKathryn Connelly, Rachel Koelmeyer, Darshini Ayton, et al.
Frontiers in Public Health|June 26, 2026
European Reference Networks as core health structures where referring genetic newborn screening positive infants: an innovative operational research frameworkFernanda Fortunato, Rita Selvatici, Jan Kirschner, et al.
Annals of the Rheumatic Diseases|November 26, 2016
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)Ronald van Vollenhoven, Alexandre Voskuyl, George Bertsias, et al.
Arthritis Care & Research|December 28, 2021
Evaluating the Construct of Damage in Systemic Lupus ErythematosusSindhu R Johnson, Dafna D Gladman, Hermine I Brunner, et al.
Nature Reviews. Rheumatology|October 6, 2022
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNETRosaria Talarico, Silvia Aguilera, Tobias Alexander, et al.
Arthritis and Rheumatism|January 4, 2012
Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter studyMara Taraborelli, Véronique Ramoni, Antonio Brucato, et al.
Clinical Reviews in Allergy & Immunology|March 16, 2021
Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected IndividualsLaura Andreoli, Cecilia Nalli, Maria Grazia Lazzaroni, et al.
Pageof 38